-
GS-441524 Workflows for LC–MS/MS Research
2026-08-28
Build more reliable antiviral and pharmacokinetic studies with a workflow that treats GS-441524 as both a biological reagent and a matrix-sensitive analytical target. The approach combines controlled DMSO formulation, parent–metabolite tracking, LC–MS/MS confirmation, and practical troubleshooting for SARS-CoV-2 research.
-
Oleanolic Acid, FXR, and Cholestatic Liver Injury
2026-08-28
The reference study identifies a linked mechanism in which oleanolic acid impairs hepatocyte tight junctions and suppresses FXR-associated bile acid efflux through BSEP and MRP2. Its combined in vivo, in vitro, imaging, and LC-MS/MS strategy provides a useful framework for studying cholestatic drug-induced liver injury and FXR-dependent transport regulation.
-
Quizartinib (AC220) for FLT3 Research
2026-08-27
Quizartinib (AC220) combines low-nanomolar FLT3 activity with a practical workflow for AML signaling, resistance, and xenograft studies. This guide translates its selectivity into assay design, troubleshooting decisions, and cross-disease applications without treating preclinical findings as clinical conclusions.
-
From TIL Biology to Better Fluorescence Data
2026-08-27
Tumor-microenvironment modulation can improve TIL yield and function, but translational decisions depend on measurement quality. This article connects the mechanistic findings of a recent microsphere-enabled TIL study with practical strategies for using the FITC Goat Anti-Mouse IgG (H+L) Antibody in immunofluorescence and flow cytometry, while addressing controls, workflow fit, and preclinical limitations.
-
3-Deazaadenosine hydrochloride: Causal Assay Guide
2026-08-26
3-Deazaadenosine hydrochloride is an S-adenosylhomocysteine hydrolase inhibitor for dissecting methylation-dependent biology. This guide translates recent IGF2BP1–m6A–TUBB4B findings into a rigorous, orthogonal assay strategy for HSC and inflammation research.
-
GPNMB-Based Model Predicts ESCC Immunotherapy Response
2026-08-26
This reference study identifies circulating soluble GPNMB as a biomarker and mechanistic driver of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-epithelial niche features, and clinicopathological variables, the authors develop a multimodal framework for response and survival prediction.
-
GS-441524: From Prodrug Biology to Assay Design
2026-08-25
Explore how GS-441524 chemistry, bioactivation, and matrix-specific LC–MS/MS analysis shape antiviral research. This guide translates recent prodrug-conversion findings into practical decisions for GS-441524 pharmacokinetics, sample handling, and assay interpretation.
-
3-Deazaadenosine in Reliable Cell Assays
2026-08-25
A scenario-based guide to using 3-Deazaadenosine (SKU B6121) in cell viability, proliferation, cytotoxicity, and methylation studies. It connects assay design, formulation, data interpretation, vendor selection, and preclinical antiviral research to documented mechanistic and product information.
-
Remdesivir (GS-5734): An Assay-First Framework
2026-08-24
Remdesivir (GS-5734) is examined through an assay-first lens that connects polymerase pharmacology with translational antiviral study design. Insights from recent Bourbon virus research clarify how to interpret potency, timing, and tissue-level outcomes without overstating cross-virus evidence.
-
GS-441524: Mechanism, PK, and Research Workflows
2026-08-24
GS-441524 is an adenine nucleoside analog studied for conversion to an active triphosphate antiviral metabolite. Recent LC–MS/MS work maps GS-441524 prodrug conversion across gastric, blood, liver, and animal pharmacokinetic models, while product-specific handling data define solvent, storage, and quality-control requirements.
-
Diphenyleneiodonium chloride for Reliable Assays
2026-08-23
Learn how Diphenyleneiodonium chloride (DPI, SKU B6326) can clarify redox-dependent viability results, cAMP signaling modulation, and oxidative stress experiments. This scenario-based guide covers formulation, controls, protocol optimization, interpretation, and practical product selection.
-
Moxifloxacin Workflows for Gyrase and Toxicity
2026-08-22
Build reproducible Moxifloxacin assays that connect bacterial DNA gyrase inhibition with retinal ganglion cell viability and metabolic-response studies. This guide combines fresh-solution handling, concentration design, mechanistic controls, and troubleshooting for antibiotic toxicity research.
-
TBXA2R–ERM Signaling in TNBC Metastasis
2026-08-21
The reference study identifies TBXA2R as an upstream GPCR activator of ezrin, radixin, and moesin, linking receptor signaling to cytoskeletal remodeling in triple-negative breast cancer. Its results connect G-protein, Rho GTPase, and SLK/LOK kinase signaling with tumor-cell motility, invasion, and metastatic colonization, while highlighting ERM function as a mechanistic dependency.
-
GS-441524: Mechanism, Evidence, and Research Use
2026-08-21
GS-441524 is a nucleoside analog that can be phosphorylated intracellularly to an active triphosphate metabolite targeting viral RNA synthesis. Current evidence supports GS-441524 antiviral research, prodrug-conversion studies, and pharmacokinetic assay development, but product purity and in vitro activity should not be interpreted as clinical efficacy.
-
Remdesivir and the Polymerase Frontier
2026-08-20
Remdesivir (GS-5734) offers translational researchers a practical bridge between nucleoside analogue pharmacology, RNA virus replication biology, and emerging polymerase structures. This article examines the evidence supporting its use in coronavirus and Ebola virus research, explains how Nipah virus polymerase architecture expands the strategic framework, and outlines disciplined workflows for interpreting potency without overextending the data.